Arizona State University

Mayo Foundation for Medical Education and Research

Sapphire Biotech, Inc.

Douglas Lake

Natalie Michelle Mitchell

Thomas E Grys

Benjamin Katchman

Thai H Ho

Douglas Faigel

Erik P Castle

Sergei Svarovsky

Alim Seit-Nebi

Glen J Weiss

Paul Hanavan

Kwasi Antwi

Janis E Blair

Maria González-Moa

Haiwei Gu

Paniz Jasbi

The present invention relates to compositions and methods relating to biomarkers that can be used for detection and treatment assessment of infectious diseases or disorders, such as fungal infection, in a subject. The present invention also provides methods of diagnosing infectious diseases or disorders and distinguishing between different types of infectious diseases or disorders (e.g., fungal infection vs bacterial infection). The present invention additionally provides kits that find use in the practice of the methods of the invention.

Biomarkers for detection and treatment assessment of infectious diseases and disorders

Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) fromand, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.

Antigen-driven detection and treatment of coccidioidomycosis

Provided herein are diagnostic methods, devices and kits for detecting neutralizing antibodies to SARS-CoV-2.

Neutralizing antibody testing and treatment

The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuclear cells the CD4+ cells in contact with MoT cells in the presence of the one or more agents suspected of modulating Treg activity; detecting activation of the CD4+ cells without or with the agent; and comparing the activation of the CD4+ cells without or with the agent, wherein a change in activation following incubation with the agent relative to the activation of the PBMCs following incubation without the agent indicates that the agent is a modulator of Treg activity.

MoT cells as a therapeutic screening tool for regulatory t-cell activity

Compounds and methods involving inhibition of the enzymatic activity of QSOX1 (FIG.). The compounds and methods can be used in treatment of neoplastic cells, for example, to suppress tumor growth and invasion in a variety of cancers, including but not limited to myeloma and cancers of the breast, kidney, and pancreas.

Anti-neoplastic compounds and methods targeting QSOX1

The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.

QSOX1 as an anti-neoplastic drug target

Coccidioidomycosis (Valley Fever) is currently diagnosed by relying on infected individuals (humans, dogs, etc.) to generate antibodies against the fungus. Since the immune response against Valley Fever can be delayed or absent in many cases, methods that detect a polypeptide or peptide component of thesp. fungus in a bodily fluid such as blood are provided.

Growing community of inventors

Scottsdale, AZ, United States of America

Douglas Lake